Trials / Completed
CompletedNCT02140047
Exploratory Clinical Study of MT-2301
Exploratory Clinical Study of MT-2301 in Healthy Infants (Phase 2)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 2 Months – 7 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered with DPT-IPV using ActHIB® as a control in healthy infants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV | 0.25mL, subcutaneous injection |
| BIOLOGICAL | Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV | 0.5mL, subcutaneous injection |
| BIOLOGICAL | Haemophilus influenza type b conjugate vaccine + DPT-IPV | 0.5mL, subcutaneous injection |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-01-01
- Completion
- 2015-09-01
- First posted
- 2014-05-16
- Last updated
- 2026-03-17
- Results posted
- 2024-09-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02140047. Inclusion in this directory is not an endorsement.